Fecal Transplants May Quash Anti-PD-1 Resistance in Melanoma

Source: MedPage Today, February 2021

A single fecal microbiota transplant (FMT) appeared to reprogram the gut microbiomes of advanced melanoma patients to overcome their primary resistance to anti-programmed cell death protein 1 (PD-1) immunotherapy, a small single-arm phase II trial found.

In the proof-of-principle study of 16 patients, investigators at the University of Pittsburgh Hillman Cancer Center administered FMT with stool from previous good responders plus anti-PD-1 immunotherapy with pembrolizumab (Keytruda) to patients for whom previous anti-PD-1 treatment had failed.

READ THE ORIGINAL FULL ARTICLE